News

BioAlliance Pharma said that the grant of the marketing authorization in the UK represents an important milestone for the company especially with the payment of E2.5 million by

On December 26, 2007, the company entered into a securities purchase agreement in connection with a private placement to a group of institutional accredited investors. In the closings,

Under the terms of the settlement, Illumina agreed, without admitting liability, to make a one-time payment to Affymetrix of $90 million. Affymetrix agreed to dismiss with prejudice all

Under the terms of the agreement, valued at up to $35 million, Celtic will take an equity stake in Inspiration as well as provide clinical development expertise and

Proceeds from the financing will be used to support the commercialization of sumatriptan DosePro for which the company submitted a new drug application (NDA) with the FDA in

The new company, called Sysmex bioMerieux will promote and commercialize the entire bioMerieux product range in Japan starting April 1, 2008. The joint venture (JV) will manage the

The agreement enables Surgical Express (SRI) to offer its full line of reprocessing services to Premier alliance members. Premier’s more than 1,500 member hospitals and 47,000 other healthcare

Oxcarbazepine tablets, marketed by Novartis as Trileptal tablets, are prescription pharmaceutical products used in treating seizures. Taro has recently settled litigation with Novartis regarding Taro’s ‘Paragraph IV’ certification

In this trial, patients will receive 75mg/m2 of Vidaza (azacitidine for injection) either intravenously or subcutaneously in combination with an oral dose of MGCD0103 in 28-day cycles. Key